EpiAxis Therapeutics, A Leader in Novel Cancer Therapy, Announces the Appointment of Three New Non-Executive DirectorsPosted by On

EpiAxis Therapeutics is a pioneering Australian pharma company that is advancing its epigenetic assets to target LSD1 as a treatment for metastatic cancer.

Our IP position, which includes our first-in-class LSD1 inhibitors, offers highly attractive assets that underline our view that we can become the leader in epigenetic control of metastatic cancer.”

— Dr. Jeremy Chrisp

SYDNEY, AUSTRALIA, July 27, 2020 /EINPresswire.com/ — Following recent advances in its preclinical and commercial development, EpiAxis has appointed Professor Pamela Munster, a highly regarded medical oncologist in the field of metastatic breast cancer and epigenetics; Keir J Loiacono, an oncology focused business development executive and intellectual property specialist; and Dr David Fuller, a pharmaceutical physician with extensive preclinical and clinical drug development expertise in oncology, to its board, effective immediately.

EpiAxis Therapeutics is a pioneering Australian domiciled pharmaceutical discovery company that is rapidly advancing its epigenetic assets that target the nuclear bound fraction of the enzyme lysine-specific demethylase 1(LSD1) as a next generation treatment for metastatic disease, with breast cancer being its lead…

Original Author Link click here to read complete story..



Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.